News
2014 sets U.S. record for drug overdose deaths
Key clinical point: Efforts to encourage safer prescribing of opioid pain relievers should be strengthened. Major finding: In 2014, opioids were...
News
More complete cytogenetic responses at 12 months with radotinib than imatinib
Key clinical point: Radotinib was associated with significantly higher complete cytogenetic responses and major molecular responses than was...
News
Nilotinib safe, effective as first-line therapy for CML-CP patients age 65 and older
Key clinical point: Age did not affect molecular response or the incidence of adverse reactions to nilotinib among patients with CML-CP. Major...
Video
VIDEO: Top-line results from Tourmaline in multiple myeloma, plus ongoing trials and treatment selection
Dr. Shaji Kumar discussed the top-line Tourmaline trial results, the status of ongoing trials with ixazomib in other combination regimens, and the...
News
ASH: Genes affecting risk, severity of chronic ITP are identified
Key clinical point: IFNA17 and IFNLR1 may be important candidate genes involved in immune regulation and sustained autoimmunity in immune...
News
ASH: Genes tag increased risk for avascular necrosis in ALL patients under age 10
Key clinical point: Gene profiles can identify ALL patients under age 10 at increased risk for avascular necrosis. Major finding: In children...
News
ASH: Genes, induction response identify high risk childhood B-lymphoblastic leukemia patients with good outcomes
Key clinical point: Knowing which patients would not benefit from further intensification of their chemotherapy might spare them possible toxicity...
News
Expert panel issues guidelines for treatment of hematologic cancers in pregnancy
The guidelines aim to ensure that timely treatment of the cancers is not delayed in pregnant women. While rare, hematologic malignancies in...
News
FDA approves mepolizumab for use in combination with other asthma drugs
Nucala (mepolizumab) has been approved for use with other asthma medicines as maintenance therapy for patients aged 12 years and older with a...